MedDataX Logo

Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy

NCT ID: NCT00629096

Last Updated: 2014-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of the study is to determine whether intracoronary infusion of autologous bone marrow mononuclear cells can improve the ventricular function of patients with idiopathic dilated cardiomyopathy.Secondary end-points will be:

1. To evaluate possible changes in patient functional capacity and
2. to identify the biological characteristics of the bone marrow graft that might influence on functional recovery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinical studies have shown that bone marrow cells can regenerate damaged myocardium after ischemic cardiopathy; however scarce information is available from patients with non-ischemic dilated cardiomyopathy. The aim of the present work is to investigate the role of intracoronary infusion of autologous marrow-derived stem cells in a phase II study in 30 patients with dilated cardiomyopathy.Before the intracoronary transplant of marrow cells as well as six and twelve months thereafter, we will compare the ventricular function measured as left-ventricular ejection fraction by angiography, magnetic resonance imaging, echocardiography and treadmill direct oxygen consumption test. Functional capacity will be monitored throughout the study. In every condition of the study we will perform at least one 30º right anterior oblique left ventricle (LV)angiogram. During each ventriculogram, attempts will be made to obtain a sinus and a post-extrasystolic beat for analysis, in order to study contractile reserve behaviours. Post-extrasystolic beats will be obtained by inducing premature beats with the catheter, once a well opacified cardiac cycle with a normal sinus beat had been filmed. In all instances, the r-r' interval of the induced premature beat and the post-extrasystolic pause will be recorded and measured.

Measurements and calculations will be made off line in our own core lab, where end-diastolic and end-systolic silhouettes were drawn using the CASS system by 2 expert angiographers who were unaware of the patient group or study conditions. LV-volumes and ejection fraction (EF) were derived and regional wall motion was analyzed. The method by Sheehan (1) was used for the asynergy study, dividing the superimposed silhouettes in 100 radii of wall shortening, from end-diastole to end-systole. The abnormal contracting segment (ACS) was defined as the percentage of radii showing akinesia or dyskinesia. The areas of the ventrivular walls having asynergy will be regionally evaluated. The serial evolution of the contractile reserve will be evaluated by the post-extrasystolic potentiation.

Coronary Flow Reserve (CFR) in all 3 coronary arteries will also be evaluated during every hemodynamic study (before treatment and 6 months after treatment). The FloMap® system (Cardiometrics; Mountain View; California) will be used. A 0.014" intracoronary Doppler guide wire will be positioned proximally in every coronary and flow velocities will be recorded continuously. Average peak velocity will be obtained at baseline and after an intracoronary bolus of Adenosine. CFR will be calculated as the ratio between maximal flow velocity during the peak effect of the adenosine injection and basal flow velocity.

Magnetic Resonance Image (MRI) studies will be performed in 3 conditions (baseline, 3-month and 1-year after treatment). Functional parameters will be obtained in each condition, including LV-volumes, LV-mass and ejection fraction

On the morning of cardiac catheterization, up to a volume of 100-150 ml of marrow will be obtained under local anesthesia by aspiration from the iliac crest. Mononuclear Bone Marrow Cells (MNBMCs) will be isolated by density gradient centrifugation over Ficoll-Hypaque technique in a sterile, semiautomated device COBE® 2991. After three washes, MNBMCs will be filtered and resuspended in 10 ml of 0.9% sodium chloride supplemented with preservative-free 0.1% heparin. Aliquots will be obtained for cell count as well as for cytofluorometric and functional analyses of the cell content.

Cells will be directly transferred to all 3 coronary arteries (50% to left anterior descending artery, 25% to the circumflex and 25% to the right coronary artery) by the use of a coaxial balloon catheter, which will be placed proximally at each artery. Balloon size will be selected according to vessel size, in order to achieve complete occlusion of the vessel and to stop flow during cell injection. So, backflow of cells is prevented and distal stagnant flow will facilitate cell exposure. The cell suspension will be injected through the distal tip of the balloon over 2 to 4 minutes.

In addition,we will try to compare all possible changes in functional parameters with biological variables obtained from the marrow graft, such as:

1. Number of cells positive for cluster of differentiation antigen (CD) CD146,CD31, CD133,CD90,CD38, CD117, CD73, CD105, CD45, Vascular endothelial growth factor receptor 2,CXC-chemokine receptor 4 and HLA-DR.
2. Functional characterization of endothelial progenitor cells and mesenchymal stem cells present in the graft by in vitro selective cultures.
3. Analysis of the in vitro chemotactic ability of the infused cells.
4. Determination of lineage-specific cardiac markers GATA-4 and Nk2.5/Csx in the infused marrow-derived cells. Correlations between these biological parameters and the effects on patient's ventricular function could highlight the role of each of the potential mechanisms implied in cell-mediated myocardial regeneration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dilated Cardiomyopathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dilated Cardiomyopathy Marrow stem cells Myocardial regeneration Mesenchymal stem cells Marrow-derived endothelial progenitor cells

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

All included patients are assigned to arm 1, in which they are treated by the intervention

Group Type EXPERIMENTAL

Intracoronary infusion of autologous bone marrow cells

Intervention Type PROCEDURE

Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intracoronary infusion of autologous bone marrow cells

Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of both genders with established clinical and angiographic diagnosis of Idiopathic Dilated Cardiomyopathy who accept to participate in the trial.
2. They should have symptoms and/or signs of heart failure, despite optimized medical treatment.
3. Angiographic ejection fraction should be less than 50%.

Exclusion Criteria

1. Associated coronary artery disease.
2. Any history or suspicion of a toxic, pharmacologic or deposit etiology.
3. Absence of resynchronization therapy.
4. Age longer than 80 years.
5. Associated malignant or pre-malignant systemic disease.
6. Associated hematologic disorder.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Iniciativa Andaluza en Terapias Avanzadas

OTHER

Sponsor Role collaborator

Fundación Pública Andaluza Progreso y Salud

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jose Suarez de Lezo, MD, PhD

Role: STUDY_CHAIR

Department of Cardiology. Reina Sofía University Hospital

I. Concepción Herrera, MD, PhD

Role: STUDY_DIRECTOR

Department of Hematology.Reina Sofia University Hospital

Manuel Pan, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Cardiology. Reina sofia University Hospital

Jose Maria Arizon, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Cardiology. Reina Sofía university Hospital

Miguel Angel Romero, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Cardiology. Reina Sofía University Hospital

Ramon Ribes, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Radiology. Reina Sofía University Hospital

Joaquin Sanchez, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Hematology. Reina Sofía Unuversity Hospital

Antonio Torrers, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Hematology. Reina Sofía University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Reina Sofía University Hospital

Córdoba, Córdoba, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EudraCT 2007-003088-36

Identifier Type: -

Identifier Source: secondary_id

TCMR0007/2006

Identifier Type: -

Identifier Source: org_study_id